RVRC Revium Rx.

CIK 0001839140 3 ready 8-Ks latest June 22, 2026, 9:42 AM ET RSS · JSON

Activity: NORMAL 0 filings / 30d vs 0 baseline Risk accumulating: repeated leadership change (2)

Ready 8-Ks 3

Latest filing June 22, 2026, 9:42 AM ET

Top materiality 0.65

Event mix leadership ×3

Sentiment 0 pos · 1 neg · 2 neu

Executive change recent →

Recent 8-K filings for RVRC

Highest-materiality recent filing

Revium Rx COO, President and Director Inna Martin resigns due to differences in expectations

June 22, 2026, 9:42 AM ET leadership materiality 0.65 negative item 5.02

Inna Martin resigned as Director, COO, and President effective June 16, 2026, due to differences in expectations with the company.
Separation agreement: employment and consultancy with Revium Ltd. ends Sep 10, 2026; vested stock option exercise period extended to Sep 30, 2028 for up to 2,440,000 shares.

Read filing →

June 22, 2026, 9:42 AM ET leadership materiality 0.65 negative item 5.02

Revium Rx COO, President and Director Inna Martin resigns due to differences in expectations

Inna Martin resigned as Director, COO, and President effective June 16, 2026, due to differences in expectations with the company.
June 1, 2026, 9:58 AM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change ×2

Revium Rx CFO Arie Gordashnikov resigns; Igor Bluvstein appointed effective May 27, 2026

Arie Gordashnikov resigned as CFO effective May 27, 2026, with no disagreement with the company.
April 20, 2026, 7:59 PM ET leadership materiality 0.55 neutral item 5.02 item 9.01

Revium Rx appoints Amir Avraham permanent CEO, Shlomi Schwartzblat as Chairman

Appointed Amir Avraham as permanent CEO (was interim since May 2025), effective Feb 1, 2026.

Executive changes

Appointed

Igor Bluvstein

Chief Financial Officer

RVRC · Revium Rx.

Effective: 2026-05-27
Filed: June 1, 2026, 9:58 AM ET

On May 27, 2026, our Board of Directors appointed Mr. Igor Bluvstein to serve as the Chief Financial Officer of the Company and of its subsidiaries, effective immediately.

Departed

Arie Gordashnikov

Chief Financial Officer

RVRC · Revium Rx.

Effective: 2026-05-27
Successor: Igor Bluvstein
Filed: June 1, 2026, 9:58 AM ET

On May 27, 2026, Mr. Arie Gordashnikov resigned from his position as Chief Financial Officer of Revium Rx.

Materiality & sentiment trend

Max materiality 0.65 · Median 0.60 · Most common event leadership

0 positive 1 negative 2 neutral

source · RVRC on sec.gov